Introduction: Who Should Undergo Diagnostics

Knowing when to seek medical evaluation can make a significant difference in detecting gastroesophageal cancer at a stage when treatment may be more effective. Anyone experiencing persistent symptoms that affect eating or digestion should consider scheduling an appointment with their doctor, even if these signs seem minor at first.^[1]

The most common reason to seek diagnostic testing is difficulty swallowing, which doctors call dysphagia. This symptom occurs when a tumor grows large enough to narrow the passage between the throat and stomach. However, because the esophagus is flexible and can stretch to accommodate food, this symptom often doesn’t appear until the cancer has already grown considerably.^[3]

Other warning signs that should prompt a medical visit include unexplained weight loss that happens without trying, persistent heartburn or indigestion that doesn’t respond to usual remedies, ongoing chest pain or discomfort behind the breastbone, and blood in vomit or stool which may appear red or make stools look very dark. Some people also experience a persistent cough, hoarseness, or a feeling of fullness after eating only small amounts of food.^[4][6]

People with certain risk factors may benefit from more vigilant monitoring even before symptoms appear. Those who have long-term gastroesophageal reflux disease, also known as GERD, where stomach acid repeatedly flows back into the esophagus, face increased risk. A condition called Barrett’s esophagus, where the cells lining the lower esophagus become abnormal due to chronic acid reflux, significantly raises the chance of developing cancer in the area where the esophagus meets the stomach.^[3][4]

Other factors that increase risk include being overweight or obese, smoking tobacco or using smokeless tobacco products, heavy alcohol consumption, and infection with a bacteria called Helicobacter pylori (H. pylori) that lives in the stomach lining. People who consume diets high in salt, smoked foods, or very hot liquids may also face higher risk. The disease is more common in men and typically affects people over 55 years old.^[4][5]

Unfortunately, routine screening for gastroesophageal cancer is not recommended in the United States for people at average risk, unlike breast or colon cancer screening. However, for those with genetic predispositions, Barrett’s esophagus, or other specific risk factors, doctors may recommend targeted screening using specialized tests such as upper endoscopy or biomarker testing to detect abnormalities before they become cancerous.^[4]

Diagnostic Methods

When symptoms suggest the possibility of gastroesophageal cancer, doctors use a combination of imaging studies, direct visualization techniques, and tissue sampling to reach an accurate diagnosis. The diagnostic process typically begins with simpler, less invasive tests and progresses to more detailed examinations if needed.^[10]

Initial Imaging Studies

Many people first undergo a barium swallow study, also called an upper gastrointestinal series. For this test, you drink a thick white liquid containing barium, which coats the inside of your esophagus and stomach. The barium shows up clearly on X-ray images, allowing doctors to see the shape and outline of these organs. Any abnormal narrowing, bulges, or irregularities that might indicate a tumor become visible. This test is non-invasive and generally well-tolerated, though the barium drink has an unpleasant chalky taste and texture.^[10]

A chest X-ray is often performed as part of the initial evaluation to check the organs and bones inside the chest for any obvious abnormalities. While this won’t diagnose cancer definitively, it can reveal signs that warrant further investigation.^[13]

Upper Endoscopy

The most important diagnostic tool for gastroesophageal cancer is upper endoscopy, also called esophagogastroduodenoscopy (EGD), gastroscopy, or simply an endoscopy. This procedure allows doctors to directly view the inside of your esophagus, stomach, and the first part of your small intestine called the duodenum.^[3][10]

During an endoscopy, a doctor passes a thin, flexible tube called an endoscope down your throat and into your esophagus. The endoscope has a tiny camera and light at its tip, which sends images to a monitor so the doctor can carefully examine the tissue lining. The procedure is usually done while you’re sedated to keep you comfortable and prevent gagging. Most people don’t remember the procedure afterward because of the sedation medication.^[10]

If the doctor sees any areas that look abnormal during the endoscopy, they can immediately take small tissue samples for laboratory analysis. This tissue sampling procedure is called a biopsy. The doctor uses special cutting tools passed through the endoscope to remove very small pieces of tissue from suspicious areas. You won’t feel pain during the biopsy because the lining of the esophagus doesn’t have pain-sensing nerves in the same way skin does.^[10]

Biopsy and Laboratory Analysis

The tissue samples collected during endoscopy are sent to a laboratory where a specialist called a pathologist examines them under a microscope. The pathologist looks for cancer cells and, if cancer is present, determines what type it is. There are two main types of gastroesophageal cancer: adenocarcinoma, which begins in glandular cells that produce mucus and typically forms in the lower esophagus near the stomach, and squamous cell carcinoma, which develops in the flat cells lining the esophagus and usually affects the upper and middle portions.^[2][9]

Cancer that forms specifically at the gastroesophageal junction, where the esophagus meets the stomach, requires careful examination because it can sometimes be difficult to distinguish from stomach cancer or esophageal cancer. Research has shown that gastroesophageal junction cancers are actually a separate type that can behave differently from cancers of the esophagus alone or stomach alone.^[3]

Staging Tests

Once cancer is confirmed through biopsy, additional tests help determine how far the disease has spread. This process is called staging, and it’s essential for planning treatment. Staging tests show whether cancer is confined to the esophagus or has spread to nearby lymph nodes or distant organs.^[3][10]

Endoscopic ultrasound combines endoscopy with ultrasound imaging. A special endoscope with an ultrasound probe at its tip is passed into the esophagus, allowing doctors to see how deeply cancer has grown into the esophageal wall and whether nearby lymph nodes appear abnormal. This test provides more detailed information than regular endoscopy alone.^[3]

Computed tomography, commonly called a CT scan, uses X-rays taken from multiple angles and computer processing to create detailed cross-sectional images of your body. CT scans can show whether cancer has spread to lymph nodes, the liver, lungs, or other organs. You may need to drink a contrast liquid or receive contrast dye through an intravenous line to make certain tissues show up more clearly on the images.^[3]

A PET-CT scan combines positron emission tomography with CT scanning. For this test, you receive a small injection of radioactive sugar. Cancer cells, which are very active and use lots of energy, absorb more of this sugar than normal cells and light up on the scan. This helps doctors find cancer that may have spread to areas not easily visible on regular CT scans.^[3]

Sometimes doctors recommend a laparoscopy, a surgical procedure where small incisions are made in the abdomen and a camera is inserted to directly view the stomach, surrounding tissues, and lymph nodes. This allows doctors to check for cancer spread that might not be visible on imaging tests. Small tissue samples can also be taken during laparoscopy for examination.^[3]

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments for gastroesophageal cancer and often have specific requirements about which patients can participate. The diagnostic tests used to qualify patients for clinical trials are more rigorous and standardized than those used in routine clinical practice, ensuring that researchers can accurately compare results across different participants and study sites.^[14]

Before enrolling in a clinical trial, patients typically undergo a comprehensive diagnostic evaluation that confirms not only the presence of cancer but also its exact characteristics. This includes detailed histological confirmation, where pathologists examine biopsy samples to determine the specific type of cancer cells, their appearance under the microscope, and how aggressive they seem to be. The distinction between adenocarcinoma and squamous cell carcinoma matters in many trials because different cancer types may respond differently to experimental treatments.^[14]

Many clinical trials require specific staging information obtained through standardized imaging protocols. Patients may need recent CT scans of the chest, abdomen, and pelvis performed according to particular technical specifications, ensuring images are of sufficient quality for study purposes. PET-CT scans are frequently required to establish baseline measurements of tumor activity that can be compared to later scans to assess whether a treatment is working.^[14]

Biomarker testing has become increasingly important for qualifying patients for targeted therapy trials. Biomarkers are molecules found in the blood, tissues, or other body fluids that indicate something about a disease. For gastroesophageal cancers, researchers often test tumor samples for specific proteins or genetic changes. For example, some trials only accept patients whose tumors have high levels of a protein called HER2, which can be targeted by certain drugs. Others look for microsatellite instability or specific gene mutations that might predict response to immunotherapy drugs.^[14]

Blood tests are standard for clinical trial screening. These include complete blood counts to check levels of red blood cells, white blood cells, and platelets, and tests of liver and kidney function to ensure these organs are working well enough to handle experimental treatments. Blood tests also establish baseline values that can be monitored throughout the trial to watch for side effects.^[14]

Some trials have very specific criteria about previous treatments. Diagnostic records must show exactly what treatments a patient has already received, how they responded, and how much time has passed since the last treatment. Patients may need to wait a certain period after completing chemotherapy or radiation therapy before qualifying for a trial testing a new approach.^[14]

Performance status scales, which measure how well a person can carry out daily activities, are commonly used to determine trial eligibility. Doctors assess whether a person can care for themselves, how much time they spend in bed or a chair, and whether they can work or do household tasks. Trials testing aggressive treatments typically require patients to have good performance status, meaning they’re active and able to care for themselves most of the time.^[14]

For trials studying treatments before surgery, precise measurements of tumor size and location are critical. Endoscopic ultrasound measurements must document how far the tumor extends into the esophageal wall and which lymph nodes appear affected. These baseline measurements allow researchers to determine whether tumors shrink in response to pre-surgical treatment.^[14]

Nutritional assessment may also be part of trial qualification, especially since gastroesophageal cancer often causes weight loss and difficulty eating. Some trials exclude patients who have lost too much weight or have severe nutritional deficiencies, while others specifically study interventions to address these problems. Doctors may measure body weight, calculate body mass index, and assess albumin levels in the blood as markers of nutritional status.^[14]